Summary of Key Points from Conference Call Records Industry Overview - The medical device sector is expected to see investment opportunities in Q2 2025 due to steady equipment updates and the end of inventory clearance by companies [1][5] - The pharmaceutical industry is projected to perform relatively flat in 2025, ranking between 10th to 15th among 31 primary industries [2] Key Insights on Specific Sectors Innovative Drugs - The innovative drug sector showed strong performance in Q1 2025, with companies like BeiGene reporting a 50% year-over-year revenue increase, and others like Innovent and Rongchang Biotech seeing growth rates of over 40% and nearly 60%, respectively [3] - Small-cap companies like Aidi Kang experienced triple-digit growth, indicating a robust market for innovative drugs [3] Medical Devices - The medical device market is witnessing a significant uptick in procurement, with a nearly 70% year-over-year increase in bidding for equipment in Q1 2025 [3][17] - Major imaging equipment and radiation therapy devices are in high demand, particularly in tertiary hospitals, with procurement rates accelerating in eastern provinces like Jiangsu and Guangdong [20][22] Traditional Chinese Medicine (TCM) - The TCM sector is expected to perform well in Q2 and Q3 2025, driven by domestic demand expansion, aging population, and state-owned enterprise reforms [1][9] - Key recommended stocks include China Resources Sanjiu, Dong-E E-Jiao, and Jianmin, with valuations currently at 15-17 times earnings [9] Pharmaceutical Retail - The pharmaceutical retail sector is undergoing a supply-side clearance, with leading chains focusing on cost reduction and efficiency to ensure profit growth [11] - Companies like Yifeng Pharmacy and Lao Bai Xing are highlighted for their operational efficiency [11] API Market - The active pharmaceutical ingredient (API) market is stabilizing after years of price declines, with companies like Huahai Pharmaceutical and Tianyu Co. reporting stable revenues around 1.4 billion [12] Future Trends and Events - Upcoming academic conferences and significant data releases from companies are expected to impact market sentiment positively [6] - The medical device sector is projected to see concentrated procurement activity in Q3 and Q4 2025, following a government push for large-scale equipment updates [17][18] Additional Insights - The in-vitro diagnostics (IVD) sector is facing pressure due to price reductions and tax adjustments, but a potential recovery is anticipated by the end of 2025 [8] - The high-value consumables market remains stable, with companies in orthopedics showing strong performance post-collective procurement [8] - The construction of tightly-knit county medical communities is expected to drive procurement in these areas, with a goal of 90% completion by the end of 2025 [23]

Investment Rating - The industry investment rating is "Positive" [1] Core Viewpoints - The second quarter is recommended for the traditional Chinese medicine sector, with expectations for a performance turning point despite significant pressure in the first quarter [3][10] - The traditional Chinese medicine sector is anticipated to see a recovery in performance due to improved inventory levels and profitability, alongside favorable conditions from U.S. tariff policies [5][21] Summary by Sections 1. Quarterly Report Overview - The first quarter faced substantial pressure, but nearly half of the companies (31) achieved positive growth in net profit attributable to shareholders after excluding non-recurring items, with 18 companies reporting revenue growth [13][14] - Companies such as Jia Ying Pharmaceutical and Te Yi Pharmaceutical reported significant revenue growth of 28.8% and 79.3%, respectively, driven by channel expansion and marketing reforms [14] 2. Core Indicator Tracking - Inventory levels have decreased, leading to sustained improvements in profitability [18] - The traditional Chinese medicine sector's valuation is currently below the average since 2021, indicating potential for recovery [24] 3. Investment Recommendations - Companies with strong brand power and potential for margin improvement are recommended for aggressive investment, including Dong E E Jiao, Tong Ren Tang, and Pian Zai Huang [10][18] - Defensive investments are suggested in stable dividend-paying assets such as Yunnan Baiyao and Ling Rui Pharmaceutical [10][18] - The sector's overall valuation is low, with a TTM price-to-earnings ratio of 27.00x as of May 9, 2025, which is below the average since 2021 [24]

Group 1 - The article discusses the challenges of long-term investing, highlighting that stocks often perform better after being sold, leading to frustration for investors [1][3][4] - It mentions specific companies like Hisense Electric and Yonghui Supermarket, illustrating the difficulties faced when holding onto underperforming stocks [1][2] - The author reflects on the unpredictability of the market, noting that stable profit companies may not yield expected returns while underperforming stocks can unexpectedly rise [3][4] Group 2 - The article emphasizes the importance of understanding market dynamics and avoiding reliance on social media opinions, which can lead to poor investment decisions [7][12] - It suggests that investors should consider low-risk options like convertible bonds or index funds, especially when market conditions are uncertain [5][12] - The discussion includes the notion that successful investing requires patience and a long-term perspective, as many stocks may take years to appreciate [11][14]

Group 1 - Shenzhen is enhancing its role as a global industrial financial hub through the "Action Plan" aimed at building a high-quality capital market that meets the needs of high-quality economic development [1] - The plan emphasizes the cultivation of "patient capital" to support long-term investments in technology innovation, with a focus on guiding state-owned and government investment funds to become more responsible long-term capital [2] - As of December 2024, Shenzhen has 1,599 private equity and venture capital fund managers, with a total management scale of 1.41 trillion yuan, leading the nation in the number of new private equity and venture capital funds [2] Group 2 - The launch of the "Technology Board" in the bond market coincided with the issuance of innovation bonds by companies like Luxshare Precision and Shenzhen Investment Control, marking a significant step in integrating finance with technology [3] - The "Action Plan" aims to create a diverse financing support system for technology companies, encouraging insurance funds to invest in specific private equity and venture capital funds [3] Group 3 - Shenzhen has 584 listed companies, ranking third in the nation, with a market capitalization of approximately 8.61 trillion yuan, highlighting the city's importance in the capital market [4] - The "Action Plan" focuses on improving the quality of listed companies by enhancing governance and promoting cash dividends, with over 2,300 billion yuan in dividends distributed in 2024 [4][5] - In 2024, Shenzhen's listed companies invested approximately 199.9 billion yuan in R&D, ranking second nationally, with a 9.54% year-on-year increase [5] Group 4 - The "Action Plan" supports the development of leading industry institutions and encourages mergers and acquisitions to strengthen the capital market ecosystem [6] - As of December 2024, Shenzhen has 23 securities companies and 3,107 private fund managers, ranking second and first nationally, respectively [6] Group 5 - The plan promotes high-level opening-up by enhancing cooperation between Shenzhen Stock Exchange and Hong Kong Stock Exchange, aiming to attract quality foreign financial institutions [7] - Shenzhen has five securities companies participating in the first batch of cross-border wealth management pilot programs, leading the nation in this initiative [7]

Core Viewpoint - The article discusses the "Action Plan" released by Shenzhen's local financial management bureau and the Shenzhen Securities Regulatory Bureau, aiming to enhance the role of the capital market in building an industrial financial center by 2025-2026, focusing on high-quality development and innovation capital aggregation [1]. Group 1: Cultivating Patient Capital - The "Action Plan" emphasizes the cultivation of "patient capital" to support long-term investments in technology innovation, with state-owned and government investment funds taking a more proactive role [3]. - As of December 2024, Shenzhen has 1,599 private equity and venture capital fund managers, with a total management scale of 1.41 trillion yuan, leading the nation in the number of new funds established in 2024 [3]. - The plan proposes optimizing the coordination between debt and equity financing for tech enterprises, supporting high-tech companies in bond financing, and facilitating participation in the new "technology board" for qualified firms [3]. Group 2: Enhancing Listed Company Value - Shenzhen has 584 listed companies, ranking third nationally, with a market capitalization of approximately 8.61 trillion yuan [6]. - The "Action Plan" aims to improve the quality of listed companies by enhancing governance, promoting cash dividends, and supporting share buybacks, with over 2,300 billion yuan in dividends distributed in 2024 [6][7]. - In 2024, Shenzhen's listed companies invested about 1,999 billion yuan in R&D, marking a 9.54% increase year-on-year, with over 170 companies in strategic emerging industries [7]. Group 3: Building a First-Class Capital Market Ecosystem - The "Action Plan" encourages leading financial institutions to strengthen through mergers and acquisitions and supports differentiated development for smaller institutions [9]. - As of December 2024, Shenzhen has 23 securities firms, 32 public fund management companies, and 3,107 private fund managers, all ranking among the top nationally [9]. - The plan supports the Shenzhen Stock Exchange in enhancing the multi-tiered capital market system, with over 700 billion yuan raised through direct financing in 2024 [10]. Group 4: Promoting Mergers and Acquisitions - The "Action Plan" highlights the role of capital markets in facilitating mergers and acquisitions, with 184 disclosed projects amounting to 406.87 billion yuan since the introduction of new policies [7]. - Shenzhen's listed companies are encouraged to strengthen industry integration and develop into industry leaders, with significant support from financial institutions for M&A loans [7].

Core Viewpoint - The financial report of Pianzaihuang for 2024 reveals significant challenges, with a 26.07% year-on-year decline in net profit for Q4, marking the lowest level since 2019, and a record low revenue growth of 7.25% over the past decade, reflecting broader difficulties faced by the traditional Chinese medicine industry [2][8]. Industry Situation - The primary challenge for Pianzaihuang is the rising cost of raw materials, particularly natural cow bile, which has surged from 650,000 yuan per kilogram to 1,650,000 yuan per kilogram over the past two years [3]. - The overall Chinese medicine sector is experiencing a collective downturn, with Pianzaihuang being relatively better off compared to other companies like Zhongsheng Pharmaceutical and Taiji Group, which reported drastic profit declines [7][8]. Financial Performance - Pianzaihuang's Q4 net profit was 290 million yuan, down 26.07% year-on-year, while the annual revenue growth was only 7.25%, the lowest in a decade [2][4]. - The company attempted to mitigate rising costs by increasing prices by 28.8% in 2023, but revenue and net profit growth rates fell to 15.69% and 13.04%, respectively, in the same year [4][5]. Cost Structure - Direct material costs account for over 90% of the total costs in various product categories, including liver disease and cardiovascular medications, indicating a heavy reliance on raw materials [4][7]. - The cost of direct materials for liver disease medications reached 164.48 million yuan, representing 96.52% of total costs, while cardiovascular medications saw a 56.1% increase in material costs year-on-year [4]. Market Dynamics - The price of Pianzaihuang's product has reached the upper limit of consumer acceptance, with retail prices significantly lower than the official price, indicating challenges in passing on costs to consumers [5]. - The collective "explosion" in the Chinese medicine sector is attributed to policy changes, including the expansion of centralized procurement, which has led to significant price reductions and profit declines for many companies [9][15]. Future Outlook - The Chinese medicine industry must address the impacts of centralized procurement policies, which have resulted in price drops and profit squeezes, while also focusing on innovation and diversification to mitigate risks associated with raw material costs [16][17]. - Companies like Pianzaihuang are exploring diversification strategies, but the effectiveness of these efforts remains limited, highlighting the need for a more robust approach to research and development [17][18].

医药生物行业 超配（维持） Q1 板块业绩承压，关注细分景气方向 医药生物行业 2024 年及 2025 年一季度业绩综述 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。请务必阅读末页声明。 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： 分析师：魏红梅 SAC 执业证书编号： S0340513040002 电话：0769-22119462 邮箱：whm2@dgzq.com.cn 医药生物（申万）指数走势 资料来源：东莞证券研究所，Wind 相关报告 证 券 研 究 报 告 业 绩 综 述 行 业 研 究 2025 年 5 月 8 日 xiexiongxiong@dgzq.com.cn ◼ 2024年行业整体营收和归母净利润同比有所下滑。2024年，SW（2021）医 药生物行业实现营业总收入2.46万亿元，同比下滑1.0%，增速同比下滑1.8 个百分点；实现归属于母公司股东的净利润1,402.6亿元，同比下降13.1%， 增速同比上 ...

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with some companies showing significant profit growth while facing challenges from high inventory and pricing pressures. The outlook for 2025 appears more optimistic due to easing macroeconomic factors and supportive policies [3][5][6]. Group 1: Market Performance - The A-share market saw major indices rise, with the Chinese Medicine ETF (560080) increasing by 0.19% and trading volume exceeding 26 million yuan, indicating active trading [1]. - Among the 49 constituent stocks of the Chinese Medicine ETF, 24 reported positive net profit growth, representing approximately 49% of the total [3]. Group 2: Company Performance - Notable profit growth was observed in companies such as Jilin Aodong (+260%), Jiaying Pharmaceutical (+197%), and Buchang Pharmaceutical (+170%) [3]. - The financial performance of several companies showed varied results, with Jilin Aodong reporting a 27.7% decline in revenue but a 259.8% increase in net profit [4]. Group 3: Industry Outlook - The Chinese medicine industry is expected to face challenges in 2024 due to high baselines and inventory digestion, but a recovery is anticipated in 2025 as macroeconomic conditions improve [5]. - Policy support, including the March 2025 guidelines for enhancing Chinese medicine quality, is expected to stimulate innovation and improve market conditions [5][6]. Group 4: Valuation and Investment Opportunities - The current valuation of the Chinese Medicine Index is at a price-to-earnings ratio of 25.77, which is below the 74.1% threshold of the past decade, indicating a relatively low valuation [8]. - Investors are encouraged to consider the Chinese Medicine ETF (560080) for potential rebound opportunities in the market [10].

Meeting Overview - The shareholders' meeting was held on May 7, 2025, at the Tianjin Beichen Technology Park [1] - The meeting was conducted with both on-site and online voting, presided over by the chairwoman, Zhou Hui [1] Attendance - Out of 15 current directors, 12 attended the meeting, while three were absent due to work commitments [2] - All 5 current supervisors attended the meeting, along with the board secretary and the financial director [2] Proposal Review - A proposal to increase the expected daily related transactions for 2025 was approved [3] - The voting for the proposal was a non-cumulative voting process, requiring a simple majority from the attending shareholders [3][4] Legal Witnessing - The meeting was legally witnessed by Inner Mongolia Jianzhong Law Firm, with lawyers Liu Hong and Zhang Xinyu present [5] - The legal opinion confirmed that the meeting's procedures and voting results were in compliance with relevant laws and regulations [5]

"如果再出现这样的机会，我会在一秒钟内做出反应，以低于市场平均市盈率水平的价格，一篮子的买 入一批大型制药股。" 对于医药股，股神巴菲特很坦诚，因为他很难去做选择，所以错过了一大批投资机会。5月3日，在今年 的股东大会上，巴菲特对于医药股更是鲜有提及。 不过，股神没有青睐的行业，并不是说没有机会。就在今年以来，A股、港股的医药板块悄然崛起，目 前累计涨幅已经超过火爆的机器人板块，而创新药板块更是成为这波上涨的"急先锋"。 来自WIND资讯的统计数据显示，截至4月30日，在港股上市的恒生生物科技指数(HSHKBIO)今年以来 表现突出，同期累计涨幅达到32.83%,而同期恒生科技指数的涨幅仅有17.37%。 更为引人关注的是，这波行情已经蔓延到医药股，就连A股相关主题基金也受益匪浅，多只医药主题基 金今年以来涨幅已经超过40%。 (1)看点一：业绩领跑 如果说今年表现最火的板块，那大多数人的第一反应，肯定是科技板块，尤其是机器人板块。不过，现 在又有了新变化。 上述统计显示，就在港股板块中，随着生物科技指数的大涨，一个不容忽视的事实是，主要投资医药尤 其是创新药板块的生物科技指数，已经大幅跑赢了恒生科技指数，而 ...